changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact firstname.lastname@example.org
Pulmonary Embolism (PE) is a condition where one or more clots break off or travel from existing venous clots in the legs or arms and travel in the circulation, getting trapped in the lung, where they block the ability of blood to get to some areas of the lung and receive oxygen. In submassive or massive cases, this may lead to a strain on the heart’s ability to pump blood through the lungs which can then lead to heart failure and/or cardiovascular collapse. PEs can be immediately fatal and are responsible for more deaths in the U.S. each year than breast cancer and AIDS combined.3,6,7
If PE can be diagnosed and appropriate therapy started, the mortality can be reduced from approximately 30 percent to less than 10 percent.8
Common PE symptoms include:
Therapy with anticoagulation may stop new clots from forming, but anticoagulation alone will not dissolve a clot that has already formed.1
The EkoSonic® Endovascular System is the only endovascular device cleared by the FDA for the treatment of Pulmonary Embolism. EKOS™ has successfully and safely treated patients with acute, massive and sub-massive PE.
The EkoSonic® Endovascular System used in conjunction with a thrombolytic drug dissolves clots and restores healthy heart function and blood flow. It improves right ventricular function and pulmonary artery pressure while minimizing the risk of bleeding.13
There is strong clinical evidence for EKOS™ therapy in the treatment of PE.
ULTIMA Trial Summary
SEATTLE II Trial Summary
I couldn’t have asked for a better treatment outcome
- Jessica Krack